FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Anderson

Research Profile

Disorders

HIV Infections

Chemicals & Drugs

Physiology

Drug Interactions

Anatomy

Leukocytes, Mononuclear

Procedures

Concepts & Ideas

Prospective Studies

Co-author Network

Publications

TOP 3
John C Schoen; Kristine M Erlandson; Peter L Anderson
Clinical pharmacokinetics of antiretroviral drugs in older persons.
Jose R Castillo-Mancilla; Caitlin Fernandez; Edward M Gardner; Jennifer J Kiser; Jacob Langness; Amie L Meditz; Julie Predhomme; Joseph E Rower; Jia-Hua Zheng; Lane Bushman; Peter L Anderson
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Christina L Aquilante; Uwe Christians; Elizabeth B Daily; Keith L Hoffman; Charles W Hopley; Jennifer J Kiser; Lisa A Kosmiski; Julie A Predhomme; Bjorn Schniedewind; Peter L Anderson; Maha S Sidhom
Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Anderson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: John C Schoen; Kristine M Erlandson; Peter L Anderson
Clinical pharmacokinetics of antiretroviral drugs in older persons.
Expert opinion on drug metabolism & toxicology 2013;9(5):573-88.
2013: Jose R Castillo-Mancilla; Caitlin Fernandez; Edward M Gardner; Jennifer J Kiser; Jacob Langness; Amie L Meditz; Julie Predhomme; Joseph E Rower; Jia-Hua Zheng; Lane Bushman; Peter L Anderson
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
AIDS research and human retroviruses 2013;29(2):384-90.
2012: Christina L Aquilante; Uwe Christians; Elizabeth B Daily; Keith L Hoffman; Charles W Hopley; Jennifer J Kiser; Lisa A Kosmiski; Julie A Predhomme; Bjorn Schniedewind; Peter L Anderson; Maha S Sidhom
Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.
Journal of clinical pharmacology 2012;52(11):1725-38.
2012: Deidre A Kile; Samantha MaWhinney; Joseph E Rower; Christina L Aquilante; Jose R Castillo-Mancilla; Peter L Anderson
A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
AIDS research and human retroviruses 2012;28(10):1227-34.
2012: Peter L Anderson; Linda-Gail Bekker; Susan Buchbinder; Lane Bushman; Martín Casapía; Suwat Chariyalertsak; David V Glidden; Robert M Grant; Juan Vicente Guanira; Esper Georges Kallás; Javier R Lama; Albert Liu; Kenneth H Mayer; Vanessa McMahan; Orlando Montoya-Herrera; Mauro Schechter; Valdilea G Veloso
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Science translational medicine 2012;4(151):151ra125.
2012: Joseph E Rower; Jia-Hua Zheng; Lane Bushman; Edward M Gardner; Brandon Klein; Kenneth A Lichtenstein; Samantha MaWhinney; Amie L Meditz; Julie Predhomme; Peter L Anderson
Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.
Antimicrobial agents and chemotherapy 2012;56(6):3011-9.
2012: Jennifer J Kiser; Peter L Anderson; James R Burton; Gregory T Everson
Review and management of drug interactions with boceprevir and telaprevir.
Hepatology (Baltimore, Md.) 2012;55(5):1620-8.
2011: Lane Bushman; Jennifer J Kiser; Brandon Klein; Michelle L Ray; Joseph E Rower; Jia-Hua Zheng; Peter L Anderson
Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection.
Journal of pharmaceutical and biomedical analysis 2011;56(2):390-401.
2011: Peter L Anderson; Jennifer J Kiser; Edward M Gardner; Joseph E Rower; Amie Meditz; Robert M Grant
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
The Journal of antimicrobial chemotherapy 2011;66(2):240-50.
2011: Laura Enomoto; Peter L Anderson; Shaobing Li; Charles L Edelstein; Adriana Weinberg
Effect of nucleoside and nucleotide analog reverse transcriptase inhibitors on cell-mediated immune functions.
AIDS research and human retroviruses 2011;27(1):47-55.
2010: Jennifer J Kiser; J Brock Bumpass; Amie L Meditz; Peter L Anderson; Lane Bushman; Michelle Ray; Julie A Predhomme; Joseph Rower; Samantha MaWhinney; Richard C Brundage
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
Antimicrobial agents and chemotherapy 2010;54(12):4999-5003.
2009: Peter L Anderson; Christina L Aquilante; Edward M Gardner; Julie Predhomme; Patrick McDaneld; Lane Bushman; Jia-Hua Zheng; Michelle Ray; Samantha MaWhinney
Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.
The Journal of antimicrobial chemotherapy 2009;64(5):1071-9.
2008: Peter L Anderson; Tracy King; Jia-Hua Zheng; Samantha MaWhinney
Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro.
The Journal of antimicrobial chemotherapy 2008;62(4):738-45.
2008: Peter L Anderson
Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs.
Current opinion in HIV and AIDS 2008;3(3):258-65.
2008: Jennifer J Kiser; Christina L Aquilante; Peter L Anderson; Tracy M King; Monica L Carten; Courtney V Fletcher
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2008;47(3):298-303.
2008: Jennifer J Kiser; M L Carten; Christina L Aquilante; Peter L Anderson; Pamela Wolfe; T M King; Thomas Delahunty; Lane Bushman; Courtney V Fletcher
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Clinical pharmacology and therapeutics 2008;83(2):265-72.
2007: Peter L Anderson; Jia-Hua Zheng; Tracy King; Lane Bushman; Julie Predhomme; Amie L Meditz; John Gerber; Courtney V Fletcher
Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.
AIDS (London, England) 2007;21(14):1849-54.
2007: Peter L Anderson; Kenneth A Lichtenstein; Nel E Gerig; Jennifer J Kiser; Lane Bushman
Atazanavir-containing renal calculi in an HIV-infected patient.
AIDS (London, England) 2007;21(8):1060-2.
2006: Tracy King; Lane Bushman; Jennifer J Kiser; Peter L Anderson; Michelle Ray; Thomas Delahunty; Courtney V Fletcher
Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;843(2):147-56.
2006: Christina L Aquilante; Taimour Y Langaee; Peter L Anderson; Issam Zineh; Courtney V Fletcher
Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.
Clinica chimica acta; international journal of clinical chemistry 2006;372(1-2):195-8.
2006: Peter L Anderson; Jatinder Lamba; Christina L Aquilante; Erin Schuetz; Courtney V Fletcher
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.
Journal of acquired immune deficiency syndromes (1999) 2006;42(4):441-9.
2006: Peter L Anderson; Thomas Kakuda
Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
The Journal of antimicrobial chemotherapy 2006;58(1):220-1.
2006: Jennifer J Kiser; Kenneth A Lichtenstein; Peter L Anderson; Courtney V Fletcher
Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection.
Pharmacotherapy 2006;26(4):511-4.
2006: Tracy King; Lane Bushman; Peter L Anderson; Thomas Delahunty; Michelle Ray; Courtney V Fletcher
Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;831(1-2):248-57.
2006: Jennifer J Kiser; Peter L Anderson; Thomas Kakuda
6th International Workshop on Clinical Pharmacology of HIV Therapy.
Expert opinion on pharmacotherapy 2006;7(2):229-41.
2005: Jennifer J Kiser; Peter L Anderson; John G Gerber
Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs.
Current HIV/AIDS reports 2005;2(2):61-7.
2004: Thomas Kakuda; Peter L Anderson; Stephen L Becker
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
AIDS (London, England) 2004;18(18):2442-4.
2004: Peter L Anderson
Pharmacologic perspectives for once-daily antiretroviral therapy.
The Annals of pharmacotherapy 2004;38(11):1924-34.
2004: Peter L Anderson; Courtney V Fletcher
Updated clinical pharmacologic considerations for HIV-1 protease inhibitors.
Current HIV/AIDS reports 2004;1(1):33-9.
2004: Peter L Anderson; Thomas Kakuda; Kenneth A Lichtenstein
The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(5):743-53.
2004: Peter L Anderson; Susan Miller; Lane Bushman
Stability of zidovudine with oxytocin in a simulated Y-site injection.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2004;61(4):394-6.
2003: Peter L Anderson; Thomas Kakuda; Sagar Kawle; Courtney V Fletcher
Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.
AIDS (London, England) 2003;17(15):2159-68.
2002: Peter L Anderson; Richard C Brundage; Thomas Kakuda; Courtney V Fletcher
CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid.
Clinical pharmacology and therapeutics 2002;71(4):280-5.
2002: Courtney V Fletcher; Peter L Anderson; Thomas Kakuda; Timothy W Schacker; Keith Henry; Cynthia R Gross; Richard C Brundage
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.
AIDS (London, England) 2002;16(4):551-60.
2001: Thomas Kakuda; LM Page; Peter L Anderson; Keith Henry; Timothy W Schacker; F S Rhame; Edward P Acosta; Richard C Brundage; Courtney V Fletcher
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.
Antimicrobial agents and chemotherapy 2001;45(1):236-42.
2000: Peter L Anderson; Richard C Brundage; Lane Bushman; Thomas Kakuda; Rory P Remmel; Courtney V Fletcher
Indinavir plasma protein binding in HIV-1-infected adults.
AIDS (London, England) 2000;14(15):2293-7.
2000: Courtney V Fletcher; Sagar Kawle; Thomas Kakuda; Peter L Anderson; Dennis Weller; Lane Bushman; Richard C Brundage; Rory P Remmel
Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.
AIDS (London, England) 2000;14(14):2137-44.
2000: S Leflore; Peter L Anderson; Courtney V Fletcher
A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections.
Drug safety : an international journal of medical toxicology and drug experience 2000;23(2):131-42.
2000: Peter L Anderson; S E Noormohamed; Keith Henry; Richard C Brundage; Henry H Balfour; Courtney V Fletcher
Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection.
Pharmacotherapy 2000;20(8):917-22.
2000: Edward P Acosta; Thomas Kakuda; Richard C Brundage; Peter L Anderson; Courtney V Fletcher
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;30 Suppl 2():S151-9.
1999: Thomas Kakuda; Richard C Brundage; Peter L Anderson; Courtney V Fletcher
Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy.
AIDS (London, England) 1999;13(16):2311-2.